Gerald E. Van Strydonck - 10 May 2024 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
Director
Signature
/s/ Maurice Zauderer, Attorney-in-Fact for Gerald E. Van Strydonck
Issuer symbol
VCNX
Transactions as of
10 May 2024
Net transactions value
+$3,122
Form type
4
Filing time
14 May 2024, 16:33:30 UTC
Previous filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCNX Common Stock Award $3,122 +543 $5.75 543 10 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCNX Stock Option (Right to Buy) Award $0 +10,108 $0.000000 10,108 10 May 2024 Common Stock 10,108 $5.75 Direct F8
holding VCNX Stock Option (Right to Buy) 426 10 May 2024 Common Stock 426 $204.00 Direct F2
holding VCNX Stock Option (Right to Buy) 166 10 May 2024 Common Stock 166 $78.90 Direct F2
holding VCNX Stock Option (Right to Buy) 514 10 May 2024 Common Stock 514 $116.70 Direct F3
holding VCNX Stock Option (Right to Buy) 159 10 May 2024 Common Stock 159 $82.80 Direct F2
holding VCNX Stock Option (Right to Buy) 123 10 May 2024 Common Stock 123 $107.55 Direct F2
holding VCNX Stock Option (Right to Buy) 182 10 May 2024 Common Stock 182 $72.75 Direct F2
holding VCNX Stock Option (Right to Buy) 1,045 10 May 2024 Common Stock 1,045 $59.25 Direct F4
holding VCNX Stock Option (Right to Buy) 1,905 10 May 2024 Common Stock 1,905 $32.25 Direct F5
holding VCNX Stock Option (Right to Buy) 3,550 10 May 2024 Common Stock 3,550 $16.80 Direct F6
holding VCNX Stock Option (Right to Buy) 9,589 10 May 2024 Common Stock 9,589 $6.15 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024.
F2 Exercisable in full as of the date of this report.
F3 This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F4 This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F5 This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F6 This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F7 This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
F8 This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.

Remarks:

All figures in this Form 4 reflect the Issuer's 1-for-14 reverse stock split effected on February 19, 2024.